EHA 2023 | The role of blinatumomab in the frontline treatment of B-ALL and considerations for elderly patients
Shaun Fleming, MBBS, FRACP, FRCPA, Alfred Hospital, Melbourne, Australia, comments on the benefit of blinatumomab in the frontline treatment of Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (Ph- B-ALL), commenting on the need to determine the optimal combination therapy for older patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen – research funding, speakers honoraria, advisory board membership
Gilead – advisory board membership
Novartis – speakers honorarium
BMS – advisory board membership, speakers honorarium
Pfizer – advisory board membership, speakers honorarium
